Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Liabilities and Shareholders Equity (2016 - 2025)

Dexcom (DXCM) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $6.3 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 2.23% to $6.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.9 billion through Dec 2025, up 6.89% year-over-year, with the annual reading at $6.3 billion for FY2025, 2.23% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $6.3 billion at Dexcom, down from $7.5 billion in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $7.5 billion in Q3 2025, with the low at $4.4 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $5.9 billion, with a median of $6.3 billion recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 79.33% in 2021, then decreased 3.67% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $4.9 billion in 2021, then grew by 9.29% to $5.4 billion in 2022, then grew by 16.19% to $6.3 billion in 2023, then grew by 3.51% to $6.5 billion in 2024, then decreased by 2.23% to $6.3 billion in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $6.3 billion, $7.5 billion, and $7.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.